Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies

Gynecologic Oncology

Volumn 139, Issue 1, 2015, Pages 118-126

  Depreeuw, Jeroen ^a,b,c   Hermans, Els ^a   Schrauwen, Stefanie ^a   Annibali, Daniela ^a   Coenegrachts, Lieve ^a   Thomas, Debby ^a   Luyckx, Mathieu ^d   Gutierrez Roelens, Ilse ^d   Debruyne, David ^e   Konings, Katrien ^a   Moerman, Philippe ^f   Vergote, Ignace ^a   Lambrechts, Diether ^b,c   Amant, Frédéric ^a,g  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e AZ GROENINGE   (Belgium)

^f DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Endometrial cancer; Patient derived tumor xenografts; Preclinical models; Targeted therapy

Indexed keywords

CARBOPLATIN; CYTOKERATIN; DACTOLISIB; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MUTS; SELUMETINIB; VIMENTIN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; GENE DOSAGE; GENETIC ANALYSIS; GENETIC SIMILARITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR ENGRAFTMENT; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; ENZYMOLOGY; GENETICS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943351035     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.07.104     Document Type: Article

References (27)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
2. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 2005 491 505
3. TCGA Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
4. A.P. Myers New strategies in endometrial cancer: targeting the PI3K/mTOR pathway - the devil is in the details Clin. Cancer Res. 19 2013 5264 5274
5. R.A. Goodwin, R. Jamal, D. Tu, W. Walsh, J. Dancey, A.M. Oza, and et al. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer Gynecol. Oncol. 131 2013 315 320
6. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, D.M. Provencher, and et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J. Clin. Oncol. 29 2011 3278 3285
7. F.I. Raynaud, S. Eccles, P.A. Clarke, A. Hayes, B. Nutley, S. Alix, and et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases Cancer Res. 67 2007 5840 5850
8. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, R.R. Broaddus, and et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
9. H.B. Salvesen, I.S. Haldorsen, and J. Trovik Markers for individualised therapy in endometrial carcinoma Lancet Oncol. 13 2012 e353 e361
10. M. Hidalgo, F. Amant, A.V. Biankin, E. Budinska, A.T. Byrne, C. Caldas, and et al. Patient-derived xenograft models: an emerging platform for translational cancer research Cancer Discov. 4 2014 998 1013
11. Z.C. Dobbin, A.A. Katre, A.D. Steg, B.K. Erickson, M.M. Shah, R.D. Alvarez, and et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer Oncotarget 5 2014 8750 8764
12. S.J. Weroha, M.A. Becker, S. Enderica-Gonzalez, S.C. Harrington, A.L. Oberg, M.J. Maurer, and et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer Clin. Cancer Res. 20 2014 1288 1297
13. H. Zhao, B. Thienpont, B.T. Yesilyurt, M. Moisse, J. Reumers, L. Coenegrachts, and et al. Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks eLife 3 2014 e02725
14. D.N. Church, E. Stelloo, R.A. Nout, N. Valtcheva, J. Depreeuw, N. ter Haar, and et al. Prognostic significance of POLE proofreading mutations in endometrial cancer J. Natl. Cancer Inst. 107 2015 402
15. J. Reumers, P. De Rijk, H. Zhao, A. Liekens, D. Smeets, J. Cleary, and et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing Nat. Biotechnol. 30 2012 61 68
16. P.A. Futreal, L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, and et al. A census of human cancer genes Nat. Rev. Cancer 4 2004 177 183
17. I. Scheinin, D. Sie, H. Bengtsson, M.A. van de Wiel, A.B. Olshen, H.F. van Thuijl, and et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly Genome Res. 24 2014 2022 2032
18. P. Van Loo, S.H. Nordgard, O.C. Lingjaerde, H.G. Russnes, I.H. Rye, W. Sun, and et al. Allele-specific copy number analysis of tumors Proc. Natl. Acad. Sci. U. S. A. 107 2010 16910 16915
19. S. Schrauwen, J. Depreeuw, L. Coenegrachts, E. Hermans, D. Lambrechts, and F. Amant Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models Gynecol. Oncol. 138 2015 165 173
20. Y.S. DeRose, G. Wang, Y.C. Lin, P.S. Bernard, S.S. Buys, M.T. Ebbert, and et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes Nat. Med. 17 2011 1514 1520
21. S. Julien, A. Merino-Trigo, L. Lacroix, M. Pocard, D. Goere, P. Mariani, and et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer Clin. Cancer Res. 18 2012 5314 5328
22. X.C. Zhang, J. Zhang, M. Li, X.S. Huang, X.N. Yang, W.Z. Zhong, and et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies J. Transl. Med. 11 2013 168
23. M. Mattie, A. Christensen, M.S. Chang, W. Yeh, S. Said, Y. Shostak, and et al. Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics Neoplasia 15 2013 1138 1150
24. E. Marangoni, A. Vincent-Salomon, N. Auger, A. Degeorges, F. Assayag, P. de Cremoux, and et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays Clin. Cancer Res. 13 2007 3989 3998
25. F. Ricci, F. Bizzaro, M. Cesca, F. Guffanti, M. Ganzinelli, A. Decio, and et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations Cancer Res. 74 2014 6980 6990
26. C. Isella, A. Terrasi, S.E. Bellomo, C. Petti, G. Galatola, A. Muratore, and et al. Stromal contribution to the colorectal cancer transcriptome Nat. Genet. 47 2015 312 319
27. M.C. Mendoza, E.E. Er, and J. Blenis The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation Trends Biochem. Sci. 36 2011 320 328